Subscribe to RSS
DOI: 10.1055/s-0035-1559666
Retrospective Pilot Study for Analysis of Antidepressant Serum Concentrations of Citalopram and Venlafaxine during Inflammation
Publication History
received 20 May 2015
revised 17 July 2015
accepted 23 July 2015
Publication Date:
03 September 2015 (online)
![](https://www.thieme-connect.de/media/pharmaco/201506/lookinside/thumbnails/2015-05-0459_10-1055-s-0035-1559666-1.jpg)
Abstract
Introduction: Inflammation-mediated changes in drug metabolism may increase drug levels in blood and lead to intoxications. The objective of this study was to find out whether elevated serum levels of C-reactive protein (CRP) are associated with increased serum concentrations of the antidepressants citalopram and venlafaxine.
Methods: Therapeutic drug monitoring request forms of psychiatric patients were screened retrospectively. The serum concentrations in relation to the daily doses [(C/D) (ng/ml/mg)] and the metabolic ratios (metabolite/drug) were compared intraindividually under normal (<5 mg/l) and pathological (>5 mg/l) condition by the Wilcoxon signed-rank test.
Results: Elevated levels of CRP were not associated with a significant (P>0.05) increase in C/D for citalopram (2.4 ng/ml/mg vs. 2.85 ng/ml/mg, N=15) or in C/D for the active moiety of venlafaxine (1.76 ng/ml/mg vs. 1.68 ng/ml/mg, N=39), compared with normal CRP serum levels. No significant difference in the metabolic ratio was observed in both groups.
Discussion: There was no major effect of inflammation on the metabolism of citalopram and venlafaxine. Because of the broad therapeutic indices of these 2 drugs, the drugs seem to be a good choice for the treatment of depression, even if an infection occurs.
-
References
- 1 Hurlimann J, Thorbecke GJ, Hochwald GM. The liver as the site of C-reactive protein formation. J Exp Med 1966; 123: 365-378
- 2 Slaviero KA, Clarke SJ, Rivory LP. Inflammatory response: an unrecognised source of variability in the pharmacokinetics and pharmacodynamics of cancer chemotherapy. Lancet Oncol 2003; 4: 224-232
- 3 Renton KW. Regulation of drug metabolism and disposition during inflammation and infection. Expert Opin Drug Metab Toxicol 2005; 1: 629-640
- 4 Aitken AE, Richardson TA, Morgan ET. Regulation of drug-metabolizing enzymes and transporters in inflammation. Annu Rev Pharmacol Toxicol 2006; 46: 123-149
- 5 Petrovic V, Teng S, Piquette-Miller M. Regulation of drug transporters during infection and inflammation. Mol Interv 2007; 7: 99-111
- 6 Hiemke C, Baumann P, Bergemann N et al. AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011. Pharmacopsychiatry 2011; 44: 195-235
- 7 Hefner G, Laib AK, Sigurdsson H et al. The value of drug and metabolite concentration in blood as a biomarker of psychopharmacological therapy. Int Rev Psychiatry 2013; 25: 494-508
- 8 Haack MJ, Bak ML, Beurskens R et al. Toxic rise of clozapine plasma concentrations in relation to inflammation. Eur Neuropsychopharmacol 2003; 13: 381-385
- 9 Pfuhlmann B, Hiemke C, Unterecker S et al. Toxic clozapine serum levels during inflammatory reactions. J Clin Psychopharmacol 2009; 29: 392-394
- 10 Shams ME, Arneth B, Hiemke C et al. CYP2D6 polymorphism and clinical effect of the antidepressant venlafaxine. J Clin Pharm Ther 2006; 31: 493-502
- 11 Greiner C, Hiemke C, Bader W et al. Determination of citalopram and escitalopram together with their active main metabolites desmethyl(es-)citalopram in human serum by column-switching high performance liquid chromatography (HPLC) and spectrophotometric detection. J Chromatogr B Analyt Technol Biomed Life Sci 2007; 848: 391-394
- 12 Schmitt G, Herbold M, Peters F. Methodenvalidierung im forensisch-toxikologischen Labor. Auswertung von Validierungsdaten nach den Richtlinien der GTFCh mit Valistat. 1st edn. Walldorf: Arvecon; 2003
- 13 Raaska K, Raitasuo V, Arstila M et al. Bacterial pneumonia can increase serum concentration of clozapine. Eur J Clin Pharmacol 2002; 58: 321-322
- 14 Abou Farha K, van Vliet A, Knegtering H et al. The value of desmethylclozapine and serum CRP in clozapine toxicity: a case report. Case Rep Psychiatry 2012; 2012: 592784
- 15 Gründer G, Hiemke C, Paulzen M et al. Therapeutic plasma concentrations of antidepressants and antipsychotics: lessons from PET imaging. Pharmacopsychiatry 2011; 44: 236-248
- 16 Renton KW. Alteration of drug biotransformation and elimination during infection and inflammation. Pharmacol Ther 2001; 92: 147-163
- 17 Iber H, Sewer MB, Barclay TB et al. Modulation of drug metabolism in infectious and inflammatory diseases. Drug Metab Rev 1999; 31: 29-41
- 18 Fogelman SM, Schmider J, Venkatakrishnan K et al. O- and N-demethylation of venlafaxine in vitro by human liver microsomes and by microsomes from cDNA-transfected cells: effect of metabolic inhibitors and SSRI antidepressants. Neuropsychopharmacology 1999; 20: 480-490
- 19 McAlpine DE, Biernacka JM, Mrazek DA et al. Effect of cytochrome P450 enzyme polymorphisms on pharmacokinetics of venlafaxine. Ther Drug Monit 2011; 33: 14-20
- 20 Brosen K, Naranjo CA. Review of pharmacokinetic and pharmacodynamic interaction studies with citalopram. Eur Neuropsychopharmacol 2001; 11: 275-283
- 21 Fudio S, Borobia AM, Pinana E et al. Evaluation of the influence of sex and CYP2C19 and CYP2D6 polymorphisms in the disposition of citalopram. Eur J Pharmacol 2010; 626: 200-204
- 22 Yin OQ, Wing YK, Cheung Y et al. Phenotype-genotype relationship and clinical effects of citalopram in Chinese patients. J Clin Psychopharmacol 2006; 26: 367-372
- 23 Harley J, Luty S, Carter J et al. Elevated C-reactive protein in depression: a predictor of good long-term outcome with antidepressants and poor outcome with psychotherapy. J Psychopharmacol 2010; 24: 625-626
- 24 Uher R, Tansey KE, Dew T et al. An inflammatory biomarker as a differential predictor of outcome of depression treatment with escitalopram and nortriptyline. Am J Psychiatry 2014; 171: 1278-1286
- 25 Unterecker S, Hiemke C, Greiner C et al. The effect of age, sex, smoking and co-medication on serum levels of venlafaxine and O-desmethylvenlafaxine under naturalistic conditions. Pharmacopsychiatry 2012; 45: 229-235
- 26 Unterecker S, Riederer P, Proft F et al. Effects of gender and age on serum concentrations of antidepressants under naturalistic conditions. J Neural Transm 2013; 120: 1237-1246